New Wave Of Anti-Depressant Drugs Approved For Use

Published: Wednesday, April 3, 2019 - 12:34pm
Updated: Wednesday, April 3, 2019 - 1:59pm
Audio icon Download mp3 (9.64 MB)

The Food and Drug Administration recently approved esketamine — in nasal spray form — to help treat major depression. And another fast-acting drug for post-partum depression has also been approved, one that's administered via an IV.

We’re seeing a period in which a new class of anti-depression drugs known as NMDAs is being introduced — following SSRIs in the 1970s and SNRIs in the 1990s.

To learn more about the impact of NMDAs and esketamine, The Show was joined by Michael Thase, a psychiatry professor at the University of Pennsylvania. He’s also received financial support from Janssen for research on esketamine.

If you like this story, Donate Now!

Like Arizona Science Desk on Facebook